<DOC>
	<DOC>NCT02156674</DOC>
	<brief_summary>This is a single center study in which NaglazymeÂ® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant.</brief_summary>
	<brief_title>Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<criteria>Mucopolysaccharidosis type VI (MPS VI, MaroteauxLamy syndrome) treated with a prior allogeneic transplant &gt;2 years previously Persons currently receiving Naglazyme may be accepted into the study Age &gt; 2 years &gt;10% engrafted based on most recent testing Willing to commit to traveling to the University of Minnesota every 6 months Written informed consent with parent/guardian consent for children &lt; 18 years of age or persons unable to consent with minor assent if appropriate History of cardiac or pulmonary insufficiency or those requiring continuous supplemental oxygen Pregnant or breastfeeding Any condition that, in the view of the investigator, places the patient at high risk of poor treatment compliance or of not completing the study</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Maroteaux-Lamy Syndrome</keyword>
	<keyword>mucopolysaccharide VI</keyword>
	<keyword>MPS VI</keyword>
</DOC>